AltMountain

Davern Capital Partners, LP

New York, NY · CRD 323018
Hedge fund manager

Davern Capital Partners, LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $715.1 million in regulatory assets under management. Its private funds, of all types, hold $55.1 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +10.6% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +10.6% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$715.1 millionForm ADV Item 5.F
Gross assets of private funds
$55.1 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
4Form ADV Item 5.A
Registration
SEC-registered adviserCRD 323018
Latest Form ADV
03/27/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+10.6%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+10.6%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$586.5 million15 positions, 2026-06-30
$95$103$111Q1 2026Q2 202613F est. $111S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+9.1%+14.8%
Q1 2026+1.3%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 17 share positions ($514,064,996) reported by Davern Capital Partners, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 12, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Biontech SE13.04%
  • Royalty Pharma PLC11.06%
  • Insmed Inc11.01%
  • Roivant Sciences LTD10.48%
  • Ionis Pharmaceuticals Inc9.44%
  • Argenx SE7.01%
  • Regeneron Pharmaceuticals6.00%
  • Natera Inc5.08%
  • Abivax SA4.22%
  • Vera Therapeutics Inc3.95%
StockValue% of 13F portfolioSharesShares vs prior quarter
Biontech SE$67,055,14813.04%682,148-9.60%
Royalty Pharma PLC$56,866,68411.06%974,412-15.69%
Insmed Inc$56,618,80511.01%496,047-11.39%
Roivant Sciences LTD$53,860,58910.48%1,472,808-23.80%
Ionis Pharmaceuticals Inc$48,540,8909.44%1,087,142-9.26%
Argenx SE$36,052,1397.01%37,597New
Regeneron Pharmaceuticals$30,832,0166.00%40,661-56.11%
Natera Inc$26,121,1925.08%63,200-46.88%
Abivax SA$21,703,5014.22%219,183New
Vera Therapeutics Inc$20,286,9673.95%628,274+25.95%
Mineralys Therapeutics Inc$17,469,1703.40%695,152-19.05%
Legend Biotech Corp$16,486,4233.21%828,880-30.44%
Arrowhead Pharmaceuticals In$15,007,6852.92%229,300New
Eli Lilly & Co$14,579,2082.84%12,600New
Generate Biomedicines Inc$12,386,6792.41%824,679Unchanged
Viridian Therapeutics Inc$11,545,0192.25%560,710New
Avalo Therapeutics Inc$8,652,8811.68%564,441+20.44%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 5 new positions, 3 sold out, 2 increased, 9 reduced and 1 unchanged.

Number of positions (a count, not dollars)

  • New positions5
  • Increased2
  • Unchanged1
  • Reduced9
  • Sold out3

New positions

StockValueShares
Argenx SE$36,052,13937,597
Abivax SA$21,703,501219,183
Arrowhead Pharmaceuticals In$15,007,685229,300
Eli Lilly & Co$14,579,20812,600
Viridian Therapeutics Inc$11,545,019560,710

Sold out

StockValue at Jun 30, 2026Shares held then
Alnylam Pharmaceuticals Inc$34,041,978113,085
Structure Therapeutics Inc$23,939,987446,059
Procept Biorobotics Corp$10,497,894464,920

Largest increases

StockChange in sharesChangeValue nowShares now
Vera Therapeutics Inc+129,442+25.95%$20,286,967628,274
Avalo Therapeutics Inc+95,775+20.44%$8,652,881564,441

Largest reductions

StockChange in sharesChangeValue nowShares now
Regeneron Pharmaceuticals-51,979-56.11%$30,832,01640,661
Natera Inc-55,775-46.88%$26,121,19263,200
Roivant Sciences LTD-460,096-23.80%$53,860,5891,472,808
Royalty Pharma PLC-181,397-15.69%$56,866,684974,412
Insmed Inc-63,777-11.39%$56,618,805496,047
Legend Biotech Corp-362,642-30.44%$16,486,423828,880
Biontech SE-72,402-9.60%$67,055,148682,148
Ionis Pharmaceuticals Inc-110,922-9.26%$48,540,8901,087,142
Mineralys Therapeutics Inc-163,601-19.05%$17,469,170695,152

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Apr 11, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠